Apogee Therapeutics, Inc. (APGE)

In the past six months, Apogee Therapeutics announced positive Phase 2 data for Zumilokibart in atopic dermatitis, demonstrating maintenance and deepening of responses with infrequent dosing. The company announced and closed a $350 million underwritten public offering, resulting in gross proceeds of $403 million. The share price as of April 2, 2026, was $84.34, representing a significant increase of 161.11% from April 7, 2025.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company with no approved products on the market and has generated zero revenue from product sales; therefore, there is no established demand seasonality for its products and services. The company's financial performance is currently characterized by capital consumption to fund research and development. While there is some seasonality analysis for APGE's stock price, suggesting a higher probability of positive returns in certain months, this relates to stock market trends rather than product demand.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology indications. The company's pipeline aims to address conditions such as atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. Its major product candidates include Zumilokibart (APG777), APG279, APG273, APG808, APG990, and APG222. Apogee's strategy involves developing antibody programs designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and optimizing half-life and other properties for differentiated efficacy and dosing.

Apogee Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States, and conducts clinical trials in North America and Europe.

Apogee Therapeutics generally holds a positive brand reputation among analysts, with a consensus rating of "Moderate Buy" and a consensus price target of $110.79. Positive clinical trial results for Zumilokibart and successful public offerings have contributed to its reputation. However, as a clinical-stage biotechnology company, Apogee faces inherent risks that can impact its reputation, such as developmental setbacks, regulatory approval failures, and commercialization challenges. The company also currently generates zero revenue, which can be a point of concern for some investors.

Apogee Therapeutics, Inc. is primarily owned by institutional shareholders (100.41%), with a smaller percentage held by Apogee Therapeutics insiders (5.44%) and retail investors (0.00%). Major institutional owners include VR Adviser, LLC, Fmr Llc, Wellington Management Group Llp, BlackRock, Inc., Vanguard Group Inc, Rtw Investments, Lp, Perceptive Advisors Llc, Driehaus Capital Management Llc, Janus Henderson Group Plc, Fairmount Funds Management LLC, and T. Rowe Price Investment Management, Inc. The largest individual shareholder is Nimish P. Shah, owning 1.75 million shares, representing 2.52% of the company.